Atara Biotherapeutics, Inc.
ATRANasdaq
$8.39
↓ -3.8%Jul 17 close · end-of-day
Price
1Y↓ -9.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$118.1M
Enterprise Value
$109.8M
P/E
—
P/S
5.1
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$23.1M
Net Income (TTM)
-$9.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-27.3%
Net Margin
-40.9%
ROE
25.4%
ROIC
—
Debt / Equity
—
Net Cash
$8.4M
Return 1Y
-13.6%
Company profile
Atara Biotherapeutics, Inc. develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
- CEO
- Pascal Touchon
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 330
- Headquarters
- California
- Website
- atarabio.com
Management & directors
- Grant-Huerta YaninaChief Accounting Officer
- Nguyen AnhcoPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
ATRA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$516,000.00↓ -99.5%
Diluted EPS-$0.29↓ -108.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $63.6M | $8.6M | $128.9M | $120.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$309.1M | -$340.5M | -$280.5M | -$276.0M | -$83.4M | $35.9M |
| Net income | -$306.6M | -$340.1M | -$228.3M | -$276.1M | -$85.4M | $32.7M |
| Diluted EPS | -$4.15 | -$3.63 | -$2.24 | -$65.19 | -$11.41 | $2.57 |
| Operating cash flow | -$180.8M | -$220.5M | -$270.4M | -$193.0M | -$68.7M | -$50.9M |
| Free cash flow | -$185.3M | -$231.1M | -$274.6M | -$194.2M | -$69.0M | -$50.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | -441.2% | -3219.5% | -64.7% | 29.7% |
| Net margin | — | — | -359.1% | -3220.9% | -66.2% | 27.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.6M | $40.2M | $32.8M | $98.1M | $17.6M | $3.5M | $1.6M | $516,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$18.2M | -$21.8M | -$12.2M | $38.8M | $3.2M | -$3.6M | -$2.6M | -$3.4M |
| Net income | -$19.0M | -$21.9M | -$12.7M | $38.0M | $2.4M | -$4.3M | -$3.4M | -$4.1M |
| Diluted EPS | -$3.10 | -$2.93 | $0.27 | $3.50 | $0.19 | -$0.32 | -$0.80 | -$0.29 |
| Operating cash flow | -$10.6M | -$4.0M | -$24.5M | -$28.1M | -$7.3M | -$9.8M | -$5.7M | -$3.1M |
| Free cash flow | -$10.7M | -$4.0M | -$24.6M | -$28.1M | -$7.3M | -$9.8M | -$5.7M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -63.7% | -54.1% | -37.3% | 39.5% | 18.2% | -103.5% | -160.7% | -652.9% |
| Net margin | -66.5% | -54.5% | -38.8% | 38.7% | 13.6% | -124.6% | -213.5% | -803.3% |
Company news
Jun 17, 2026
Jun 12, 2026
May 21, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | Cherry Brian N | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-06-09 | HEIDEN WILLIAM K | Award | 12,000 | $0.00 | $0.00 | filing |
| 2026-06-09 | Fust Matthew K | Award | 12,000 | $0.00 | $0.00 | filing |
| 2026-06-09 | Ciongoli Gregory Austin | Award | 12,000 | $0.00 | $0.00 | filing |
| 2026-05-18 | Nguyen AnhCo· President and CEO | Sale | 5,241 | $9.13 | $47,844.56 | filing |
| 2026-05-18 | Grant-Huerta Yanina· Chief Accounting Officer | Sale | 2,414 | $9.13 | $22,036.44 | filing |
| 2026-05-07 | EcoR1 Capital, LLC | Buy | 507,407 | $9.35 | $4.7M | filing |
| 2026-05-07 | Panacea Innovation Ltd | Sale | 313,446 | $10.10 | $3.2M | filing |
| 2026-03-17 | Panacea Innovation Ltd | Tax withholding | 5 | $5.23 | $26.15 | filing |
| 2026-03-17 | Panacea Innovation Ltd | Option exercise | 259,163 | $0.00 | $25.92 | filing |
| 2026-03-09 | Grant-Huerta Yanina· Chief Accounting Officer | Award | 20,300 | $0.00 | $0.00 | filing |
| 2026-03-09 | Nguyen AnhCo· President and CEO | Award | 81,100 | $0.00 | $0.00 | filing |
| 2026-03-02 | Grant-Huerta Yanina· Chief Accounting Officer | Sale | 1,603 | $5.08 | $8,144.84 | filing |
| 2026-03-02 | Nguyen AnhCo· President and CEO | Sale | 1,442 | $5.09 | $7,335.45 | filing |
| 2026-03-02 | Nguyen AnhCo· President and CEO | Sale | 1,298 | $5.09 | $6,601.63 | filing |
| 2026-03-02 | Grant-Huerta Yanina· Chief Accounting Officer | Sale | 377 | $5.08 | $1,915.91 | filing |
| 2026-03-02 | Nguyen AnhCo· President and CEO | Sale | 198 | $5.08 | $1,005.64 | filing |
| 2026-03-02 | Grant-Huerta Yanina· Chief Accounting Officer | Sale | 100 | $5.08 | $508.30 | filing |
| 2026-03-02 | Nguyen AnhCo· President and CEO | Sale | 58 | $5.08 | $294.64 | filing |
| 2026-03-02 | Grant-Huerta Yanina· Chief Accounting Officer | Sale | 24 | $5.08 | $121.85 | filing |
| 2026-01-12 | Panacea Innovation Ltd | Sale | 80,554 | $6.07 | $489,019.17 | filing |
| 2025-11-28 | Panacea Innovation Ltd | Tax withholding | 1 | $14.03 | $14.03 | filing |
| 2025-11-28 | Panacea Innovation Ltd | Option exercise | 48,737 | $0.00 | $4.87 | filing |
| 2025-11-17 | Nguyen AnhCo· President and CEO | Sale | 2,859 | $13.19 | $37,698.77 | filing |
| 2025-11-17 | Grant-Huerta Yanina· Chief Accounting Officer | Sale | 1,645 | $13.19 | $21,690.97 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.